Kane Biotech Inc (KNE) - Total Assets
Based on the latest financial reports, Kane Biotech Inc (KNE) holds total assets worth CA$2.73 Million CAD (≈ $1.98 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kane Biotech Inc - Total Assets Trend (2003–2025)
This chart illustrates how Kane Biotech Inc's total assets have evolved over time, based on quarterly financial data. Also see KNE company net worth for the company's overall valuation and market capitalisation.
Kane Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Kane Biotech Inc's total assets of CA$2.73 Million consist of 61.8% current assets and 38.2% non-current assets. Review Kane Biotech Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 33.0% |
| Accounts Receivable | CA$14.30K | 0.5% |
| Inventory | CA$504.56K | 18.5% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$568.30K | 20.8% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Kane Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Kane Biotech Inc (KNE) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kane Biotech Inc's current assets represent 61.8% of total assets in 2025, a decrease from 85.6% in 2003.
- Cash Position: Cash and equivalents constituted 33.0% of total assets in 2025, down from 81.4% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 7.0% in 2003.
- Asset Diversification: The largest asset category is intangible assets at 20.8% of total assets.
Kane Biotech Inc Competitors by Total Assets
Key competitors of Kane Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Kane Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.68 | 0.43 | 0.69 |
| Quick Ratio | 0.47 | 0.27 | 0.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-812.62K | CA$-1.38 Million | CA$-958.75K |
Kane Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Kane Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 104.38 |
| Latest Market Cap to Assets Ratio | 1.44 |
| Asset Growth Rate (YoY) | 9.6% |
| Total Assets | CA$2.73 Million |
| Market Capitalization | $3.95 Million USD |
Valuation Analysis
Above Book Valuation: The market values Kane Biotech Inc's assets above their book value (1.44x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Kane Biotech Inc's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kane Biotech Inc (2003–2025)
The table below shows the annual total assets of Kane Biotech Inc from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$2.73 Million ≈ $1.98 Million |
+9.62% |
| 2024-12-31 | CA$2.49 Million ≈ $1.80 Million |
-56.10% |
| 2023-12-31 | CA$5.68 Million ≈ $4.11 Million |
+1.09% |
| 2022-12-31 | CA$5.62 Million ≈ $4.07 Million |
-8.39% |
| 2021-12-31 | CA$6.13 Million ≈ $4.44 Million |
+21.82% |
| 2020-12-31 | CA$5.04 Million ≈ $3.64 Million |
+82.74% |
| 2019-12-31 | CA$2.76 Million ≈ $1.99 Million |
+77.11% |
| 2018-12-31 | CA$1.56 Million ≈ $1.13 Million |
-54.20% |
| 2017-12-31 | CA$3.40 Million ≈ $2.46 Million |
+59.40% |
| 2016-12-31 | CA$2.13 Million ≈ $1.54 Million |
+81.67% |
| 2015-12-31 | CA$1.17 Million ≈ $848.61K |
-41.03% |
| 2014-12-31 | CA$1.99 Million ≈ $1.44 Million |
+5.62% |
| 2013-12-31 | CA$1.88 Million ≈ $1.36 Million |
-25.40% |
| 2012-12-31 | CA$2.52 Million ≈ $1.83 Million |
+2.19% |
| 2011-12-31 | CA$2.47 Million ≈ $1.79 Million |
+96.98% |
| 2010-12-31 | CA$1.25 Million ≈ $907.39K |
-32.78% |
| 2009-12-31 | CA$1.87 Million ≈ $1.35 Million |
+18.67% |
| 2008-12-31 | CA$1.57 Million ≈ $1.14 Million |
+27.98% |
| 2007-12-31 | CA$1.23 Million ≈ $888.74K |
-19.04% |
| 2006-12-31 | CA$1.52 Million ≈ $1.10 Million |
+31.73% |
| 2005-12-31 | CA$1.15 Million ≈ $833.38K |
+118.87% |
| 2004-12-31 | CA$526.37K ≈ $380.77K |
-48.00% |
| 2003-12-31 | CA$1.01 Million ≈ $732.28K |
-- |
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the … Read more